Cytokinetics says heart disease drug more effective than standard-of-care, shares jump

Cytokinetics, Incorporated

02/09/2025 11:17

** Shares of drug developer Cytokinetics CYTK.O rise 32.5% to $46.79 premarket

** On Saturday, co said its experimental drug, aficamten, outperformed standard-of-care treatment, metoprolol, in improving heart function and symptoms in obstructive hypertrophic cardiomyopathy patients

** Over half of aficamten-treated patients showed better physical ability and quality of life, co said

** Co plans to seek expanded approval next year, with an FDA decision expected by December

** Obstructive hypertrophic cardiomyopathy is a genetic condition where thickened heart muscle blocks blood flow, and can lead to cardiac arrest

** As of last close, stock was down 25% YTD

 (Reporting by Kamal Choudhury in Bengaluru)

 ((Kamal.Choudhury@thomsonreuters.com;))